Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 21 Issue 3, March 2024

Monitoring coeliac disease, inspired by the Evidence-Based Guidelines on p198.

Cover design: Laura Marshall.

Editorial

  • The Editors of Nature Reviews Gastroenterology & Hepatology travel regularly to conferences to meet with the research community and keep up to date on the latest research and key trends in the field. Come and say hello!

    Editorial

    Advertisement

Top of page ⤴

Comment

Top of page ⤴

Clinical Outlook

  • A substantial percentage of patients with inflammatory bowel disease (IBD) exhibit biologic treatment failure or loss of response over time. This article explores the effectiveness and safety of monoclonal antibodies targeting the IL-23 pathway in treating IBD; continued research is needed to address lingering questions regarding long-term safety and efficacy.

    • Silvio Danese
    • Laurent Peyrin-Biroulet
    Clinical Outlook
Top of page ⤴

Research Highlights

Top of page ⤴

Reviews

Top of page ⤴

Evidence-based Guidelines

Top of page ⤴

Search

Quick links